See more : GC China Turbine Corp. (GCHT) Income Statement Analysis – Financial Results
Complete financial analysis of TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TaiGen Biopharmaceuticals Holdings Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Panbela Therapeutics, Inc. (PBLA) Income Statement Analysis – Financial Results
- 20 Microns Limited (20MICRONS.BO) Income Statement Analysis – Financial Results
- Ocwen Financial Corporation (OCN) Income Statement Analysis – Financial Results
- Resilient REIT Limited (RES.JO) Income Statement Analysis – Financial Results
- Patterson Companies, Inc. (0KGB.L) Income Statement Analysis – Financial Results
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
About TaiGen Biopharmaceuticals Holdings Limited
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 123.13M | 36.23M | 1.29B | 23.42M | 20.31M | 29.62M | 553.21M | 146.02M | 78.00M | 104.60M | 69.88M | 40.44M | 225.73M | 14.91M |
| Cost of Revenue | 11.45M | 3.74M | 12.72M | 4.04M | 7.60M | 3.56M | 6.25M | 15.39M | 19.87M | 17.56M | 15.27M | 12.15M | 28.97M | 11.54M |
| Gross Profit | 111.69M | 32.49M | 1.28B | 19.39M | 12.71M | 26.05M | 546.96M | 130.63M | 58.14M | 87.04M | 54.61M | 28.29M | 196.76M | 3.36M |
| Gross Profit Ratio | 90.70% | 89.69% | 99.02% | 82.77% | 62.57% | 87.97% | 98.87% | 89.46% | 74.53% | 83.21% | 78.15% | 69.96% | 87.16% | 22.56% |
| Research & Development | 187.48M | 237.52M | 283.28M | 249.44M | 223.56M | 197.55M | 190.68M | 263.91M | 401.44M | 386.10M | 440.37M | 415.05M | 323.98M | 381.65M |
| General & Administrative | 98.90M | 72.64M | 99.06M | 77.27M | 66.29M | 86.90M | 95.85M | 104.44M | 87.91M | 109.53M | 110.82M | 109.49M | 88.67M | 72.80M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 98.90M | 72.64M | 99.06M | 77.27M | 66.29M | 86.90M | 95.85M | 104.44M | 87.91M | 109.53M | 110.82M | 109.49M | 88.67M | 72.80M |
| Other Expenses | 0.00 | 9.00K | 41.00K | 0.00 | 153.89M | 328.00K | 425.00K | 674.00K | 15.26M | 14.65M | 59.23M | 24.31M | -98.49M | 14.91M |
| Operating Expenses | 258.78M | 310.16M | 382.34M | 326.71M | 289.84M | 284.45M | 286.53M | 368.34M | 489.35M | 495.63M | 551.19M | 524.54M | 412.66M | 454.45M |
| Cost & Expenses | 297.83M | 313.90M | 395.06M | 330.74M | 297.45M | 288.02M | 292.78M | 383.73M | 509.21M | 513.19M | 566.46M | 536.68M | 441.63M | 465.99M |
| Interest Income | 20.38M | 8.72M | 4.23M | 3.50M | 8.62M | 20.10M | 16.86M | 5.27M | 6.38M | 21.45M | 6.59M | 2.74M | 3.78M | 4.78M |
| Interest Expense | 1.14M | 854.00K | 244.00K | 601.00K | 1.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 27.61M | 28.55M | 28.86M | 31.43M | 34.32M | 10.96M | 10.28M | 9.35M | 9.55M | 8.58M | 9.51M | 11.91M | 22.50M | 28.81M |
| EBITDA | 172.23M | -200.37M | 928.34M | -261.80M | -264.95M | -332.25M | 270.70M | -230.73M | -424.72M | -399.72M | -489.86M | -491.00M | -193.40M | -422.27M |
| EBITDA Ratio | 139.87% | -520.58% | 69.92% | -1,589.76% | -1,244.05% | -838.14% | 48.92% | -156.00% | -537.14% | -382.43% | -697.06% | -1,197.67% | -243.07% | 9,483.41% |
| Operating Income | -174.70M | -217.15M | 876.24M | -403.78M | -287.04M | -258.40M | 260.43M | -237.71M | -431.21M | -408.59M | -496.58M | -496.24M | -215.90M | -451.08M |
| Operating Income Ratio | -141.88% | -599.37% | 67.69% | -1,723.95% | -1,412.99% | -872.43% | 47.08% | -162.79% | -552.80% | -390.63% | -710.67% | -1,227.11% | -95.64% | -3,026.19% |
| Total Other Income/Expenses | 318.19M | 47.91M | -23.47M | -99.56M | -13.04M | -84.81M | 485.95M | -12.32M | 18.22M | 8.95M | 64.39M | 21.17M | 258.73M | -1.83B |
| Income Before Tax | 143.49M | -229.77M | 875.99M | -406.87M | -290.18M | -343.21M | 746.38M | -250.03M | -412.99M | -397.65M | -432.19M | -468.40M | 42.84M | -2.29B |
| Income Before Tax Ratio | 116.53% | -634.18% | 67.67% | -1,737.14% | -1,428.45% | -1,158.79% | 134.92% | -171.23% | -529.45% | -380.17% | -618.52% | -1,158.25% | 18.98% | -15,333.54% |
| Income Tax Expense | 6.76M | 7.40M | 100.37M | -2.06M | 5.51M | -84.81M | -94.00K | 562.00K | 2.68M | 6.07M | 0.00 | 0.00 | -355.29M | 1.84B |
| Net Income | 136.73M | -237.16M | 775.62M | -404.82M | -295.69M | -343.21M | 746.38M | -250.03M | -412.99M | -403.72M | -432.19M | -468.40M | 42.84M | -2.29B |
| Net Income Ratio | 111.04% | -654.61% | 59.92% | -1,728.37% | -1,455.57% | -1,158.79% | 134.92% | -171.23% | -529.45% | -385.97% | -618.52% | -1,158.25% | 18.98% | -15,333.54% |
| EPS | 0.19 | -0.33 | 1.08 | -0.56 | -0.41 | -0.48 | 1.04 | -0.35 | -0.59 | -0.58 | -0.66 | -0.80 | 0.14 | -110.90 |
| EPS Diluted | 0.19 | -0.33 | 1.08 | -0.56 | -0.41 | -0.48 | 1.04 | -0.35 | -0.59 | -0.58 | -0.66 | -0.79 | -0.54 | -4.05 |
| Weighted Avg Shares Out | 716.90M | 716.84M | 716.84M | 716.84M | 716.81M | 716.76M | 716.76M | 713.81M | 696.75M | 695.79M | 651.89M | 588.35M | 304.07M | 20.61M |
| Weighted Avg Shares Out (Dil) | 717.27M | 716.84M | 717.36M | 716.84M | 716.81M | 716.76M | 717.14M | 713.81M | 696.75M | 697.82M | 653.80M | 590.07M | 580.55M | 564.43M |
Source: https://incomestatements.info
Category: Stock Reports